 CHARLOTTESVILLE, Va., Aug. 10, 2021 GLOBE NEWSWIRE -- Adial Pharmaceuticals, Inc. NASDAQ: ADIL; ADILW Adial or the Company, a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on recently issued patents for the use of Adials lead asset, AD04, for the treatment of both Alcohol Use Disorder AUD and Opioid Use Disorder OUD. AD04 is currently being evaluated in the Companys ONWARD trial, a Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with AUD, which is being conducted in seven countries. 